0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SOD1

SOD1

Brief Information

Name:Superoxide dismutase
Target Synonym:SOD1,Superoxide Dismutase 1,HSod1,Amyotrophic Lateral Sclerosis 1 (Adult),Epididymis Secretory Protein Li 44,Superoxide Dismutase [Cu-Zn],Cu/Zn Superoxide Dismutase,Indophenoloxidase A,SOD, Soluble,EC 1.15.1.1,HEL-S-44,IPOA,ALS1,SOD,ALS,Superoxide Dismuta
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:7
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
SO1-H5148 Human Human SOD1 / Cu-Zn SOD Protein, His Tag
SO1-H5148-structure
SO1-H5148-sds

Synonym Name

SOD1,Superoxide dismutase 1,hSod1

Background

Superoxide dismutase [Cu-Zn] (SOD1) is also known as superoxide dismutase 1 (hSod1), an enzyme that in humans is encoded by the SOD1 gene, located on chromosome 21. SOD1 can bind copper and zinc ions and is one of three superoxide dismutases responsible for destroying free superoxide radicals in the body. The encoded isozyme (SOD1) is a soluble cytoplasmic and mitochondrial intermembrane space protein, acting as a homodimer to convert naturally occurring, but harmful, superoxide radicals to molecular oxygen and hydrogen peroxide. Furthermore, the mutations of SOD1 gene can result in a neurodegenerative disorder affecting upper motor neurons in the brain and lower motor neurons in the brain stem and spinal cord.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Orgotein Approved Gt Biopharma Ontosein Spain Rheumatic Diseases; Cystitis; Radiation Injuries null 1996-01-01 Cystitis; Radiation Injuries; Rheumatic Diseases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NI-005 AP-101 (AL-S Pharma); NI-005 Phase 1 Clinical Al-S Pharma Ag Amyotrophic Lateral Sclerosis Details
BMX-010 BMX-010; MnTE-2-PyP; MnTE-2-PyP5+ Phase 2 Clinical Duke University Acne Vulgaris; Rosacea; Psoriasis; Dermatitis, Atopic; Hepatitis C, Chronic Details
AEOL-10150 AEOL-10150 Phase 1 Clinical Aeolus Pharmaceuticals Idiopathic Pulmonary Fibrosis; Neoplasms Details
Stroquinan SP-8203; SP8203 HCL; SP-8203 hydrochloride Phase 2 Clinical Shin Poong Pharmaceutical Stroke Details
GC-4711 GC-4711 Phase 2 Clinical Galera Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Avasopasem manganese GC-4419; KM-4419; M-40419; SC-72325A Phase 3 Clinical Galera, Metaphore Pharmaceuticals, Activbiotics Head and Neck Neoplasms; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophagitis; Mouth Neoplasms; Carcinoma, Squamous Cell; Stomatitis Details
Bis-choline tetrathiomolybdate ATN-224; WTX-101; ALXN-1840 Phase 3 Clinical Wilson Therapeutics Multiple Myeloma; Hepatolenticular Degeneration; Prostatic Neoplasms; Melanoma Details
Tofersen BIIB-067; ISIS-333611; 99mTc-MAG3-BIIB067 Phase 3 Clinical Ionis, Ludwig Institute For Cancer Research Amyotrophic Lateral Sclerosis Details

This web search service is supported by Google Inc.

totop